Gallbladder cancer and cholangiocarcinoma are both biliary cancers. They can cause the same symptoms, but causes and treatments can differ. Gallbladder cancer is cancer of the gallbladder, while ...

Camrelizumab plus concurrent capecitabine and radiotherapy (combination treatment) improved overall survival (OS) and recurrence-free survival in patients with resectable extrahepatic ...

(Boston)—In the United States, approximately 55% of resected gallbladder cancer (GBC) patients undergo oncologic surgery without additional systemic treatment. However, as GBC progresses to the ...

Gallbladder cancer in females can cause symptoms such as jaundice, abdominal pain, and loss of appetite. Symptoms may not appear until the cancer advances. While gallbladder cancer is more common in ...

Gallbladder cancer is a challenge because of its subtle progression and its tendency to escape early detection. Although it is a relatively rare form of cancer, it is often not diagnosed until it ...

Clinical Associate Professor of Medicine, Department of Internal Medicine and Gastroenterology, MCP Hahnemann University, Philadelphia, Pennsylvania; Chief, Division of Internal Medicine, Department ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific and overall survival significantly. Chemoradiation did not enhance relapse ...

Recurrence-free survival dynamics following adjuvant chemotherapy for resected non-colorectal cancers of the gastrointestinal tract: A systematic review of randomized controlled trials. Donafenib plus ...

A new study suggests a blood test could distinguish gallbladder cancer from gallstones by tracking changes in metabolites and bile acids.

Gallstones are a common digestive condition, particularly among women and individuals over the age of 40. In most cases, ...

The biliary tract cancer epidemiology section provides insights into the historical and current biliary tract cancer patient pool and forecasted trends for the leading markets. In 2024, the majority ...